Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)e2-e3
JournalThe Lancet Haematology
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hodgkin Disease

ASJC Scopus subject areas

  • Hematology

Cite this

Sintilimab : another effective immune checkpoint inhibitor in classical Hodgkin lymphoma. / Ansell, Stephen Maxted.

In: The Lancet Haematology, Vol. 6, No. 1, 01.01.2019, p. e2-e3.

Research output: Contribution to journalComment/debate

@article{14a02464ba5c4d389eadbce99fd1f5f6,
title = "Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma",
author = "Ansell, {Stephen Maxted}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/S2352-3026(18)30210-2",
language = "English (US)",
volume = "6",
pages = "e2--e3",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Sintilimab

T2 - another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

AU - Ansell, Stephen Maxted

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85059346064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059346064&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(18)30210-2

DO - 10.1016/S2352-3026(18)30210-2

M3 - Comment/debate

C2 - 30612711

AN - SCOPUS:85059346064

VL - 6

SP - e2-e3

JO - The Lancet Haematology

JF - The Lancet Haematology

SN - 2352-3026

IS - 1

ER -